London startup TrialReach hauled in $13.5 million in Series B cash, funds that will help expand its technology designed to connect patients with their ideal clinical trials.
The company, founded in 2010, culls together clinical trial listings from around the world and plugs their various attributes into its system, allowing patients to search for the studies that are right for them.
Visiting TrialReach.com, patients are greeted with a simple "What's your condition?" and asked where they live. Hitting search brings up all the relevant trials, sorted by proximity. And, on the other end, the platform gives study sponsors the chance to edit their listings and describe their trials in patient-friendly language to make the process less intimidating.
 |
| Pablo Graiver |
TrialReach is already working with the World Health Organization and more than half of the top 25 drugmakers, the company said. Now, with a new financing from Smedvig Capital, Amadeus Capital Partners and Octopus Investments, the U.K. startup is looking to scale up its presence in the U.S., CEO Pablo Graiver said.
"We have had significant success in the U.S. market to date, and we are confident that now it's the right time to scale up our team and operations domestically, in order to solidify our leadership position," Graiver said in a statement. "... We eagerly anticipate the opening of our New York office to jumpstart our business and sales efforts across the U.S."
- read the statement